JPWO2022018516A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022018516A5
JPWO2022018516A5 JP2023512663A JP2023512663A JPWO2022018516A5 JP WO2022018516 A5 JPWO2022018516 A5 JP WO2022018516A5 JP 2023512663 A JP2023512663 A JP 2023512663A JP 2023512663 A JP2023512663 A JP 2023512663A JP WO2022018516 A5 JPWO2022018516 A5 JP WO2022018516A5
Authority
JP
Japan
Prior art keywords
promoter
sequence
seq
aav
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023512663A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540464A (ja
JP2023540464A5 (https=
JP7842082B2 (ja
Publication date
Priority claimed from CN202010706505.5A external-priority patent/CN113952473A/zh
Priority claimed from CN202010706658.XA external-priority patent/CN113952474A/zh
Application filed filed Critical
Priority claimed from PCT/IB2021/000498 external-priority patent/WO2022018516A1/en
Publication of JP2023540464A publication Critical patent/JP2023540464A/ja
Publication of JPWO2022018516A5 publication Critical patent/JPWO2022018516A5/ja
Publication of JP2023540464A5 publication Critical patent/JP2023540464A5/ja
Application granted granted Critical
Publication of JP7842082B2 publication Critical patent/JP7842082B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023512663A 2020-07-21 2021-07-20 眼疾患を処置するための組成物および方法 Active JP7842082B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010706505.5A CN113952473A (zh) 2020-07-21 2020-07-21 用于治疗眼部疾病的组合物和方法
CN202010706658.XA CN113952474A (zh) 2020-07-21 2020-07-21 用于治疗眼部疾病的组合物和方法
PCT/IB2021/000498 WO2022018516A1 (en) 2020-07-21 2021-07-20 Composition and method for treating eye diseases

Publications (4)

Publication Number Publication Date
JP2023540464A JP2023540464A (ja) 2023-09-25
JPWO2022018516A5 true JPWO2022018516A5 (https=) 2024-07-26
JP2023540464A5 JP2023540464A5 (https=) 2024-07-26
JP7842082B2 JP7842082B2 (ja) 2026-04-07

Family

ID=79728536

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023512663A Active JP7842082B2 (ja) 2020-07-21 2021-07-20 眼疾患を処置するための組成物および方法

Country Status (7)

Country Link
US (1) US20230295243A1 (https=)
EP (1) EP4185333A4 (https=)
JP (1) JP7842082B2 (https=)
CN (1) CN116323949A (https=)
AU (1) AU2021313839A1 (https=)
CA (1) CA3186830A1 (https=)
WO (1) WO2022018516A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020006435A (es) 2017-12-19 2021-02-09 Akouos Inc Administracion de anticuerpos terapeuticos mediada por vector de virus adenoasociado (aav) en el oido interno.
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
JP2025506383A (ja) * 2022-02-02 2025-03-11 アドヴェラム バイオテクノロジーズ, インコーポレイテッド アフリベルセプトをコードするaav2バリアントを使用して眼内血管新生疾患を処置する方法
JP2026509829A (ja) * 2023-03-10 2026-03-25 アドヴェラム バイオテクノロジーズ, インコーポレイテッド 昆虫細胞における組換えアデノ随伴ウイルス(rAAV)産生
AU2024315262A1 (en) * 2023-08-03 2026-02-26 Arcum Vision Inc. Enhanced formulation of polymyxin b/ trimethoprim and rifampin and methods for ophthalmic uses

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004037611B4 (de) * 2004-08-03 2013-10-02 Geneart Ag Induzierbare Genexpression
WO2006015789A2 (de) * 2004-08-03 2006-02-16 Geneart Ag Verfahren zur modulation der genexpression durch änderung des cpg gehalts
CN105026433B (zh) * 2014-01-24 2018-10-19 上海恒瑞医药有限公司 VEGF与PDGFRβ双特异性融合蛋白及其用途
CA2977355A1 (en) * 2015-02-20 2016-08-25 University Of Iowa Research Foundation Methods and compositions for treating genetic eye diseases
DK3471780T3 (da) * 2016-06-16 2020-11-23 Adverum Biotechnologies Inc Behandling af amd med aav2-variant med aflibercept
AU2018350990A1 (en) * 2017-10-18 2020-05-21 Regenxbio Inc. Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap
DK3717636T5 (da) * 2017-11-27 2024-08-26 4D Molecular Therapeutics Inc Adeno-associeret-virus-variantcapsider og anvendelse til inhibering af angiogenese
MX2020006435A (es) * 2017-12-19 2021-02-09 Akouos Inc Administracion de anticuerpos terapeuticos mediada por vector de virus adenoasociado (aav) en el oido interno.
CA3094465A1 (en) * 2018-04-03 2019-10-10 Stridebio, Inc. Virus vectors for targeting ophthalmic tissues
WO2020102645A1 (en) * 2018-11-16 2020-05-22 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus for treating pompe disease
FI4027983T3 (fi) * 2019-09-11 2026-02-03 Adverum Biotechnologies Inc Silmän neovaskulaaristen sairauksien hoito afliberseptiä koodaavilla aav2-varianteilla
MX2023004377A (es) * 2020-10-16 2023-06-28 Gyroscope Therapeutics Ltd Acido nucleico que codifica una entidad anti-vegf y un regulador del complemento negativo y sus usos para el tratamiento de la degeneracion macular relacionada con la edad.
CA3210368A1 (en) * 2021-04-09 2022-10-13 Shengjiang Liu Compositions and methods for ocular transgene expression
KR20240004316A (ko) * 2021-04-27 2024-01-11 4디 몰레큘러 테라퓨틱스 아이엔씨. 혈관신생과 관련된 안구 질환의 치료를 위한 조성물 및 방법
MX2023014041A (es) * 2021-05-28 2023-12-15 Shanghai Regenelead Therapies Co Ltd Virus adenoasociado recombinante que tiene una capsida variante y su aplicacion.

Similar Documents

Publication Publication Date Title
JP7492556B2 (ja) 滲出型加齢性黄斑変性の治療のための組成物
JP7842082B2 (ja) 眼疾患を処置するための組成物および方法
JP7410522B2 (ja) 抗fam19a5抗体のアデノ関連ウイルス(aav)伝達
CN113966236A (zh) 眼睛病状的基因疗法
CA3090293A1 (en) Compositions for treatment of wet age-related macular degeneration
US20250340900A1 (en) Aav drug for treating angiogenesis-related fundus diseases
CN108103104B (zh) 一种预防和治疗脉络膜新生血管相关眼部疾病的基因药物
CN110423281A (zh) 用于治疗老年性黄斑变性的融合蛋白、病毒载体和药物
JPWO2022018516A5 (https=)
US20240269327A1 (en) Compositions and methods for transgene expression
US20230321281A1 (en) Compositions and methods for the treatment of eye diseases
CN113952474A (zh) 用于治疗眼部疾病的组合物和方法
CN113952473A (zh) 用于治疗眼部疾病的组合物和方法
HK40092768A (zh) 用於治疗眼部疾病的组合物和方法
WO2024238853A1 (en) Adeno-associated viruses for ocular delivery of gene therapy
AU2024322589A1 (en) Compositions and methods for expressing therapeutics
HK40090167A (zh) 一种抗vegf抗体体内表达系统的构建和应用
HK40091511A (zh) 一种抗vegf抗体体内表达系统的构建和应用
CN113952471A (zh) 用于治疗眼部疾病的组合物和方法
WO2025217230A1 (en) Vectorized anti-complement antibodies and complement agents and administration thereof
HK40092791A (zh) 用於治疗眼疾病的组合物和方法
JPWO2022018518A5 (https=)
NZ746729B2 (en) Compositions for treatment of wet age-related macular degeneration
NZ787237A (en) Compositions For Treatment of Wet Age-Related Macular Degeneration
NZ787256A (en) Compositions For Treatment of Wet Age-Related Macular Degeneration